OasisLMS

This lecture is designed to address a critical and contemporary clinical challenge: understanding the impact of cannabis and its constituent cannabinoids on individuals with Opioid Use Disorder (OUD). The session is structured into five segments, each offering insights into different aspects of this multifaceted issue:

1) Cannabis Pharmacology and Policy Evolution: We begin by delving into the fundamental pharmacological properties of cannabis and its cannabinoids. This segment will also cover the rapidly evolving landscape of cannabinoid regulation and policy changes across various U.S. states, setting the stage for understanding the broader implications of cannabis use in clinical settings.

2) Addressing OUD Treatment Challenges: The second segment shifts focus to the complexities in treating OUD. We will explore why and how non-opioid substances, including cannabinoids, have been viewed by some as potential adjunctive interventions in OUD management, highlighting the gaps in current treatment approaches and the quest for more effective strategies.

3) Cannabinoids: Preclinical and Human Study Insights: This part of the lecture will present an overview of the latest findings from both preclinical and human studies. The discussion will revolve around the potential pain-relieving properties of cannabinoids, their putative role in suppressing opioid withdrawal symptoms, and their potential opioid-sparing effects, providing a scientific basis for the investigation of their risk/benefit profile in persons with OUD.

4) Cannabinoid Effects in OUD - New Findings: Here, we will focus on groundbreaking data specifically related to persons with OUD. Special attention will be given to recent research on the acute effects of delta-9-tetrahydrocannabinol (THC), the primary psychoactive component of cannabis, derived from randomized, placebo-controlled studies conducted in our laboratory.

5) Moderating Factors and Clinical Implications: The final segment of the lecture will discuss potential moderators influencing the response to cannabinoids in individuals with OUD. It aims to equip clinicians and researchers with nuanced insights and practical considerations for applying this knowledge in real-world scenarios.

In short, this lecture seeks to be an accessible educational intervention on intersection of cannabis, cannabinoids, and OUD, offering valuable perspectives for healthcare professionals and researchers engaged in this rapidly evolving field.

1. Grasp Cannabis Pharmacology and Regulatory Changes: Gain an understanding of the basic pharmacological properties of cannabis and its cannabinoids, and stay informed about recent policy changes affecting their clinical use, particularly in opioid use disorder (OUD) treatment.
2. Understand the State of the Evidence on Potential Pain-Relieving, Opioid-Withdrawal Suppressing, and Opioid-Sparing Effects of Cannabinoids. This objective includes an exploration of both preclinical and human studies to provide a well-rounded view of current evidence in this area.
3. Apply Research Insights on Cannabinoids in OUD: Understand and apply recent findings from studies on the effects of cannabinoids, such as delta-9-tetrahydrocannabinol (THC), in OUD, focusing on clinical implications and factors influencing patient response to these treatments.
4. Identify and Manage Problematic Patterns of Cannabis Use in Persons with OUD: Develop skills to recognize and address problematic cannabis use and cannabis use disorder in individuals with OUD, integrating strategies for evaluation and intervention that complement OUD treatment.

• Help is here! The Opioid Response Network (ORN) is your resource for no-cost education, training and consultation to enhance efforts addressing opioid and stimulant use disorders.
  
• ORN has consultants in every state and territory to deploy across prevention, treatment, recovery and harm reduction.
  
• Share your needs via the “Submit a Request” form at www.OpioidResponseNetwork.org. Within one business day, your regional point person will be in touch to learn more.

ACCREDITATION:
This actvity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association and The American Osteopathic Academy of Addiction Medicine (AOAAM). The American Osteopathic Association is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT HOURS:
The American Osteopathic Association designates this other activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

DISCLOSURE AND CONFLICT OF INTEREST RESOLUTION:
All conflicts of interest of any individual(s) in a position to control the content of this CME activity will be identified and resolved prior to this educational activity being provided. Disclosure about provider and faculty relationships, or the lack thereof, will be provided to learners.

Funding for this initiative was made possible (in part) by grant no. 1H79TI085588-02 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.